Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Other financing activities (2019 - 2026)

Oric Pharmaceuticals filings provide 5 years of Other financing activities readings, the most recent being $993000.0 for Q1 2026.

  • Quarterly Other financing activities changed N/A to $993000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Mar 2026, changed N/A year-over-year, with the annual reading at $2.4 million for FY2025, 1326.79% up from the prior year.
  • Other financing activities hit $993000.0 in Q1 2026 for Oric Pharmaceuticals, down from $1.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $1.7 million in Q3 2025 and bottomed at $168000.0 in Q1 2024.
  • Average Other financing activities over 3 years is $889500.0, with a median of $824500.0 recorded in 2025.